UFR2709, an Antagonist of Nicotinic Acetylcholine Receptors, Delays the Acquisition and Reduces Long-Term Ethanol Intake in Alcohol-Preferring UChB Bibulous Rats.

UChB rats UFR2709 nicotinic antagonist voluntary ethanol intake

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
22 Jun 2022
Historique:
received: 25 05 2022
revised: 13 06 2022
accepted: 14 06 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Alcoholism is a worldwide public health problem with high economic cost and which affects health and social behavior. It is estimated that alcoholism kills 3 million people globally, while in Chile it is responsible for around 9 thousand deaths per year. Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels expressed in the central nervous system, and they were suggested to modulate the ethanol mechanism involved in abuse and dependence. Previous work demonstrated a short-term treatment with UFR2709, a nAChRs antagonist, which reduced ethanol intake using a two-bottle free-choice paradigm in University of Chile bibulous (UChB) rats. Here, we present evidence of the UFR2709 efficacy in reducing the acquisition and long-term ethanol consumption. Our results show that UFR2709 (2.5 mg/kg i.p.) reduces the seek behavior and ethanol intake, even when the drug administration was stopped, and induced a reduction in the overall ethanol intake by around 55%. Using naïve UChB bibulous rats, we demonstrate that UFR2709 could delay and reduce the genetically adaptive impulse to seek and drink ethanol and prevent its excessive intake.

Identifiants

pubmed: 35884787
pii: biomedicines10071482
doi: 10.3390/biomedicines10071482
pmc: PMC9312520
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : FONDECYT
ID : 1150615
Organisme : FONDECYT
ID : 1160398
Organisme : FONDECYT
ID : 1200474
Organisme : FONDECYT
ID : 1201577
Organisme : FONDECYT
ID : 3220275

Références

Alcohol Clin Exp Res. 2002 Jun;26(6):765-72
pubmed: 12068243
Brain Res. 1985 Dec 2;348(2):355-8
pubmed: 4075093
Front Pharmacol. 2019 Dec 03;10:1429
pubmed: 31849674
J Pharmacol Exp Ther. 1993 Sep;266(3):1390-7
pubmed: 8371144
Science. 1989 Mar 31;243(4899):1721-4
pubmed: 2467382
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Neuropsychopharmacology. 2011 Feb;36(3):603-15
pubmed: 21048701
Front Neurosci. 2015 Jan 15;8:426
pubmed: 25642160
Addict Biol. 2006 Sep;11(3-4):310-23
pubmed: 16961761
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):257-64
pubmed: 21111768
Neuropharmacology. 2007 Mar;52(3):985-94
pubmed: 17157884
Behav Brain Res. 2018 Sep 3;349:169-176
pubmed: 29704599
Alcohol Clin Exp Res. 2011 Mar;35(3):540-9
pubmed: 21143250
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12518-23
pubmed: 17626178
Nat Neurosci. 2005 Nov;8(11):1465-70
pubmed: 16251989
Alcohol Clin Exp Res. 2000 Feb;24(2):155-63
pubmed: 10698366
Alcohol Alcohol. 2005 Sep-Oct;40(5):349-58
pubmed: 16043436
Neurochem Int. 1999 Aug;35(2):131-41
pubmed: 10405997
Physiol Rev. 2009 Jan;89(1):73-120
pubmed: 19126755
Prog Brain Res. 2014;211:201-33
pubmed: 24968782
J Med Chem. 2005 May 19;48(10):3474-7
pubmed: 15887955
Eur J Pharmacol. 1998 Oct 9;358(3):189-96
pubmed: 9822883
Alcohol Clin Exp Res. 2013 Apr;37(4):655-62
pubmed: 23164049
Neurosci Biobehav Rev. 2006;30(2):215-38
pubmed: 16099045
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
pubmed: 2899326
Br J Pharmacol. 2010 May;160(2):334-45
pubmed: 20331614
Neuropsychopharmacology. 2010 Jan;35(1):217-38
pubmed: 19710631
Alcohol. 2019 Sep;79:1-6
pubmed: 30496781
Eur J Pharmacol. 1997 Sep 10;334(2-3):149-56
pubmed: 9369343
Arch Gen Psychiatry. 2007 Nov;64(11):1313-20
pubmed: 17984400
Bioorg Med Chem. 2013 May 15;21(10):2687-94
pubmed: 23561269
Mol Pharmacol. 1994 Jan;45(1):142-9
pubmed: 8302273
Psychopharmacology (Berl). 2013 May;227(2):287-98
pubmed: 23344555
Mil Med. 1998 Mar;163(3):133-8
pubmed: 9542850
J Neurophysiol. 1997 Mar;77(3):1306-12
pubmed: 9084598
Alcohol Clin Exp Res. 2002 Mar;26(3):394-9
pubmed: 11923594
Psychopharmacology (Berl). 2010 Mar;208(4):613-26
pubmed: 20072781
Psychopharmacology (Berl). 2012 Oct;223(3):299-306
pubmed: 22547331
Brain Res Bull. 1992 Aug;29(2):173-8
pubmed: 1525672
Alcohol Clin Exp Res. 1991 Mar;15(2):270-6
pubmed: 2058804
Eur J Pharmacol. 1996 Dec 30;318(2-3):257-65
pubmed: 9016913
Eur J Pharmacol. 1990 Oct 2;187(1):127-30
pubmed: 1703076
CNS Neurol Disord Drug Targets. 2010 Mar;9(1):60-76
pubmed: 20201817
Neuron. 2016 Apr 20;90(2):333-47
pubmed: 27100197
Alcohol Clin Exp Res. 2003 Oct;27(10):1535-47
pubmed: 14574223
Trends Pharmacol Sci. 2006 Sep;27(9):482-91
pubmed: 16876883
Neurobehav Toxicol Teratol. 1983 Mar-Apr;5(2):171-8
pubmed: 6683362
Front Psychiatry. 2013 Apr 30;4:29
pubmed: 23641218
Drug Alcohol Depend. 2007 Dec 1;91(2-3):149-58
pubmed: 17597309
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20368-73
pubmed: 19064933
Alcohol Alcohol. 2003 Nov-Dec;38(6):606-12
pubmed: 14633650
Alcohol. 1996 Jul-Aug;13(4):355-7
pubmed: 8836323
Alcohol Clin Exp Res. 2010 Dec;34(12):2053-60
pubmed: 20946306
Br J Pharmacol. 1992 Apr;105(4):849-56
pubmed: 1504716
Alcohol Res Health. 2006;29(3):179-85
pubmed: 17373406
Neuron. 2002 Oct 10;36(2):229-40
pubmed: 12383779
Alcohol Clin Exp Res. 2002 Dec;26(12):1919-21
pubmed: 12500120
Am J Psychiatry. 2005 Aug;162(8):1403-13
pubmed: 16055761
Alcohol Res Health. 2006;29(3):162-71
pubmed: 17373404
Cancer Res. 2009 Sep 1;69(17):6848-56
pubmed: 19706762

Auteurs

Gabriel Gálvez (G)

Laboratory of Experimental Pharmacology, Faculty of Chemical Sciences and Pharmacy, University of Chile, Santiago 8380494, Chile.

Juan Pablo González-Gutiérrez (JP)

Instituto de Ciencias Químicas Aplicadas, Facultad de Ingeniería, Universidad Autónoma de Chile, Talca 3467987, Chile.

Martín Hödar-Salazar (M)

Programa de Doctorado en Ciencias, Mención Biología Celular y Molecular Aplicada, Universidad de La Frontera, Temuco 4811230, Chile.
Laboratorio de Farmacología Molecular y Química Medicinal, Facultad de Ingeniería y Ciencias, Universidad de La frontera, Temuco 4811230, Chile.

Ramón Sotomayor-Zárate (R)

Centro de Neurobiología y Fisiopatología Integrativa (CENFI), Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso 2360102, Chile.

María Elena Quintanilla (ME)

Program of Molecular and Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile, Santiago 8380494, Chile.

María Elena Quilaqueo (ME)

Laboratory of Experimental Pharmacology, Faculty of Chemical Sciences and Pharmacy, University of Chile, Santiago 8380494, Chile.

Mario Rivera-Meza (M)

Laboratory of Experimental Pharmacology, Faculty of Chemical Sciences and Pharmacy, University of Chile, Santiago 8380494, Chile.

Patricio Iturriaga-Vásquez (P)

Laboratorio de Farmacología Molecular y Química Medicinal, Facultad de Ingeniería y Ciencias, Universidad de La frontera, Temuco 4811230, Chile.

Classifications MeSH